Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test

The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajjadi, Elham, Guerini-Rocco, Elena, De Camilli, Elisa, Pala, Oriana, Mazzarol, Giovanni, Venetis, Konstantinos, Ivanova, Mariia, Fusco, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106673/
https://www.ncbi.nlm.nih.gov/pubmed/37077201
http://dx.doi.org/10.3389/fmolb.2023.1176309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106673/
https://www.ncbi.nlm.nih.gov/pubmed/37077201
http://dx.doi.org/10.3389/fmolb.2023.1176309

Ejemplares similares